3 New Strong Buy Ratings from Top-Rated Analysts: 01/08/2026

All of these stocks have Zen Ratings of A and high levels of analyst support (here’s where we found them)...

• Our proprietary AI Factor pinpointed Neurocrine Biosciences (NBIX) as a high-potential trade
• Viatris (VTRS) has exciting projects in the pipeline
• Analysts believe Supernus Pharmaceuticals (SUPN) has a strong trajectory ahead

A note from our sponsors...

1. Neurocrine Biosciences (NASDAQ: NBIX)

Neurocrine Biosciences discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders, with a portfolio including treatments for tardive dyskinesia, Parkinson's disease, and other CNS conditions. The company is showcasing R&D transformation driving innovation across neuroscience and endocrinology with strong analyst backing.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $136.76 — get current quote

Max 1-year forecast: $203.00

Why we're watching:

• Analyst support: NBIX enjoys strong support, with 11 Strong Buy ratings, 5 Buy ratings, and 1 Hold rating from 17 analysts we track. See the ratings
• For example, Citigroup researcher Yigal Nochomovitz (top 10%) maintains a Strong Buy rating with the street-high price target of $203, which, if achieved, would represent nearly 50% upside. They recently raised their price target after NBIX reported Q3 earnings, highlighting the company’s significant consensus beat in the quarter and the fact that their Crenessity product has all the hallmarks of a blockbuster.
• Industry ranking context: NBIX is currently the 5th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
• Zen Rating highlights: NBIX has a Zen Rating of A or Strong Buy, meaning it’s in the top 5% of stocks we track.  
• Component Grades: Neurocrine shows outstanding performance with an A in Artificial Intelligence and B grades across Value, Growth, Sentiment, and Financials, indicating strong fundamentals and innovative capabilities, though Safety receives a C grade. See all 7 Zen Component Grades here

2. Viatris (NASDAQ: VTRS)

Viatris operates as a global healthcare company across Developed Markets, Greater China, JANZ, and Emerging Markets segments, focusing on generic and specialty pharmaceuticals. The company recently received FDA approval for generic Sandostatin and is advancing multiple pipeline programs with strong analyst support.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $12.56 — get current quote

Max 1-year forecast: $15.00

Why we're watching:

• Only two analysts we track issue ratings on VTRS, but they’re both Strong Buy ratings, with an average 1-year forecast that suggests over 20% potential upside in the next year. See the ratings
• One of the analysts covering the stock, Truist Securities' Srikripa Devarakonda (a top 15% rated analyst) initiated their Strong Buy rating stating that Viatris is uniquely positioned to leverage its integrated model for sustainable profitability and that innovations in product lines will create new revenue streams.
• The other analyst, Glen Santangelo of Barclays, highlighted Viatris' robust pipeline and strong positioning to capture growth in generic pharmaceutical spaces, with upcoming FDA approvals for key products serving as a catalyst.
• Industry ranking context: VTRS is currently the 13th highest-rated stock out of 56 in the Pharmaceutical industry, which has an Industry Rating of B.
• It has an overall Zen Rating of A — once again, it’s in the top 5% of the 4600+ stocks we track based on a 115-factor review. 
• Component Grades: Viatris demonstrates solid fundamentals with B grades across Value, Growth, Sentiment, and Safety, reflecting attractive valuation, growth potential, and risk management, though Financials, Momentum, and AI receive C grades. See all 7 Zen Component Grades here

3. Supernus Pharmaceuticals (NASDAQ: SUPN)

Supernus Pharmaceuticals focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company is gaining momentum with its Onapgo continuous subcutaneous infusion pump for advanced Parkinson's disease, which analysts believe has a promising trajectory.

Zen Rating: A (Strong Buy) — see full analysis

Recent Price: $49.40 — get current quote

Max 1-year forecast: $65.00

Why we're watching:

• SUPN has a bullish consensus among the analysts we track — 4 Strong Buy ratings and 1 Hold rating from 5 analysts covering the stock. See the ratings
• Cantor Fitzgerald's Kristen Kluska (a top 2% rated analyst) maintains a Strong Buy rating with a $63 price target, representing +27.53% upside potential.
• Piper Sandler researcher David Amsellem (top 6%) upgraded to Strong Buy with a $65 price target, noting that Onapgo has a promising trajectory and is not heavily dependent on promotions, which bodes well for the company's ability to expand margins and increase EBITDA.
• Industry ranking context: SUPN is currently the 10th highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
• Zen Rating highlights: As an A or Strong Buy-rated stock in the Zen Ratings system, SUPN is in the top tier of the stocks we track — A-rated stocks have historically generated 32.52% average annual returns for the past 20+ years. 
• Component Grades: Supernus shows outstanding performance with an A in Artificial Intelligence and B grades across Value, Growth, Sentiment, and Safety, indicating innovative capabilities and balanced fundamentals, though Financials receive a C grade. See all 7 Zen Component Grades here

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.